Last reviewed 2026-04-23 · How we verify

PIP/TAZ FDC

PIP/TAZ is a fixed-dose combination of piperacillin (a broad-spectrum beta-lactam antibiotic) and tazobactam (a beta-lactamase inhibitor) that works together to kill bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.

PIP/TAZ is a fixed-dose combination of piperacillin (a broad-spectrum beta-lactam antibiotic) and tazobactam (a beta-lactamase inhibitor) that works together to kill bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation. Used for Bacterial infections (broad-spectrum coverage for intra-abdominal, gynecological, skin, and respiratory tract infections).

At a glance

Mechanism of action

Piperacillin is an extended-spectrum penicillin that binds to penicillin-binding proteins and disrupts bacterial cell wall synthesis. Tazobactam is a beta-lactamase inhibitor that irreversibly binds to and inactivates many beta-lactamases, preventing bacterial resistance mechanisms that would otherwise destroy piperacillin. Together, they provide enhanced coverage against beta-lactamase-producing gram-positive and gram-negative bacteria, as well as anaerobes.

Approved indications

• Bacterial infections (broad-spectrum coverage for intra-abdominal, gynecological, skin, and respiratory tract infections)

Common side effects

• Diarrhea
• Nausea
• Vomiting
• Rash
• Headache
• Clostridium difficile-associated diarrhea
• Allergic reactions

Key clinical trials

• Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016) (PHASE3)
• Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.